trending Market Intelligence /marketintelligence/en/news-insights/trending/MXoZU05b__7RODpx5k0slg2 content esgSubNav
In This List

Inovio's Zika vaccine invokes response in first human study

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Inovio's Zika vaccine invokes response in first human study

Inovio Pharmaceuticals Inc.'s DNA-based Zika vaccine, GLS-5700, invoked an immune response and was considered to have a positive safety profile in its first human study.

Inovio had previously released data indicating that the vaccine protected animals from the infection.

In the phase 1 clinical trial, known as ZIKA-001, the vaccine induced high levels of binding antibodies in 100% of participants.

"Results from this published study demonstrate that all human subjects responded to the vaccine and that the immune responses have the ability to confer protection in challenge models. A second phase 1 study, now fully enrolled in Puerto Rico, is designed with a placebo control to explore a potential trend towards clinical efficacy," Inovio President and CEO J. Joseph Kim said in a statement.

Inovio is developing GLS-5700 in collaboration with GeneOne Life Science Inc. and The Wistar Institute.

It is also studying the vaccine for dengue virus-positive individuals.